Streetbeat News

MGRX

Mangoceuticals, Inc.

https://www.mangorx.com

Industry

Medical - Healthcare Information Services

Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Open

2.42

Mkt cap

4.6M

Volume

70K

High

2.42

P/E Ratio

-0.36

52-wk high

16.80

Low

2.27

Div yield

N/A

52-wk low

2.10

In Friday's after-market session, several consumer staples stocks experienced significant movements. Chanson International (CHSN) saw a notable increase of 75.5%, while TDH Holdings (PETZ) rose by 11.11%. On the downside, Elevai Labs (ELAB) fell by 7.2%, and Blue Star Foods (BSFC) decreased by 5.36%.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 8:31 pm

Several consumer staples stocks experienced significant price movements during Friday's intraday session. Notable gainers included Chanson International, Safety Shot, Laird Superfood, Molson Coors Beverage, Farmer Bros, and Maison Solutions. On the losing side, Elevai Labs, Big Tree Cloud Holdings, Innovation Beverage Group, China Jo-Jo Drugstores, and Mangoceuticals saw declines.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:32 pm

MangoRx has launched an oral version of Tirzepatide, a GLP-1 receptor agonist, aimed at providing advanced weight loss solutions. The product is priced at $399 per month.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:35 pm

In Thursday's pre-market session, several consumer staples stocks experienced significant movements. Notable gainers included Elevai Labs, Splash Beverage Group, and Edible Garden, while Moolec Science and Mangoceuticals were among the losers.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 12:06 pm

The article highlights the intraday movements of consumer staples stocks on Tuesday. Notable gainers include Paranovus Enter, United Natural Foods, and Mangoceuticals, while significant losers include Guardion Health Sciences and Better Choice Co.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 4:31 pm

Mangoceuticals shares rose following the announcement that their oral semaglutide product, branded as 'Slim', is now available on their website.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:23 pm

Mangoceuticals has launched its new weight loss treatment, 'Slim,' which is an oral semaglutide available as a dissolvable tablet compounded with Vitamin B6. The product is now available on the company's website.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 11:34 am

Mangoceuticals reported its financial results for the quarter ended June 30. The company posted an EPS of $(0.09), an improvement from $(0.14) year-over-year. Revenue increased to $163,163 from $141,237 year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:30 pm

Mangoceuticals reported a significant increase in shareholder equity for the first half of the year, rising to $13.829 million compared to $7.774 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:27 pm

Mangoceuticals, Inc. (NASDAQ:MGRX) has received a Certificate of Grant for its respiratory illness and preventive care technology patent in India. The patent, originally applied for by Intramont Technologies, Inc., is valid for 20 years until March 16, 2040.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.